Biologics in inflammatory immune-mediated systemic diseases

Current Pharmaceutical Biotechnology

Volumn 18, Issue 12, 2017, Pages 1008-1016

  Moroncini, Gianluca ^a   Calogerà, Giovanni ^a   Benfaremo, Devis ^a   Gabrielli, Armando ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

ANCA associated vasculitis; Beh et Disease; Belimumab; Rituximab; Systemic lupus erythematosus (SLE); Systemic sclerosis (SSc); TNF inhibitors; Tocilizumab

Indexed keywords

ADALIMUMAB; ANAKINRA; ANIFROLUMAB; ATACICEPT; AZATHIOPRINE; BELIMUMAB; BIOLOGICAL PRODUCT; CANAKINUMAB; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; NATALIZUMAB; OCRELIZUMAB; PLACEBO; PREDNISONE; RILONACEPT; RITUXIMAB; SIRUKUMAB; STEROID; TOCILIZUMAB; USTEKINUMAB; TUMOR NECROSIS FACTOR;

ANCA ASSOCIATED VASCULITIS; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CELL ACTIVATION; CONTROLLED STUDY; CROHN DISEASE; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; CYTOPENIA; CYTOTOXICITY; DRUG SAFETY; EFFICACY PARAMETERS; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; FORCED VITAL CAPACITY; GIANT CELL ARTERITIS; HIP PAIN; HODGKIN DISEASE; HUMAN; HYPERSENSITIVITY; IMMUNE FUNCTION TEST; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTERFERON GAMMA RELEASE ASSAY; LEUKOENCEPHALOPATHY; LUNG HEMORRHAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MYALGIA; PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SKIN REDNESS; SWELLING; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85045412778     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201019666171226152448     Document Type: Review

References (74)

1. Scott, D.L. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin. Pharmacol. Ther., 2012, 91(1), 30-43.
2. Mekinian, A.; Néel, A.; Sibilia, J.; Cohen, P.; Connault, J.; Lambert, M.; Federici, L.; Berthier, S.; Fiessinger, J.N.; Godeau, B.; Marie, I.; Guillevin, L.; Hamidou, M.; Fain, O.; Club Rhumatismes et Inflammation, French Vasculitis Study Group and Société Nationale Française de Médecine Interne. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford), 2012, 51(5), 882-886.
3. Al-Bishri, J.; le Riche, N.; Pope, J.E. Refractory polyarteritis nodosa successfully treated with infliximab. J. Rheumatol., 2005, 32(7), 1371-1373.
4. Takeuchi, M.; Kezuka, T.; Sugita, S.; Keino, H.; Namba, K.; Kaburaki, T.; Maruyama, K.; Nakai, K.; Hijioka, K.; Shibuya, E.; Komae, K.; Hori, J.; Ohguro, N.; Sonoda, K.H.; Mizuki, N.; Okada, A.A.; Ishibashi, T.; Goto, H.; Mochizuki, M. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: A multicenter study. Ophthalmology, 2014 121(10), 1877-1884.
5. Cantini, F.; Niccoli, L.; Nannini, C.; Kaloudi, O.; Cassarà E.; Susini M.; Lenzetti, I. Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: A prospective, follow-up study of 50 patients. Biologics, 2012, 6, 5-12.
6. Lee, J.H.; Cheon, J.H.; Jeon, S.W.; Ye, B.D.; Yang, S.K.; Kim, Y.H.; Lee, K.M.; Im, J.P.; Kim, J.S.; Lee, C.K.; Kim, H.J.; Kim, E.Y.; Kim, K.O.; Jang, B.I.; Kim, W.H. Efficacy of infliximab in intestinal Behçet’s disease: A Korean multicenter retrospective study. Inflamm. Bowel Dis., 2013, 19(9), 1833-1338.
7. Suematsu, R.; Tashiro, S.; Ono, N.; Koarada, S.; Ohta, A.; Tada, Y. Successful golimumab therapy in four patients with refractory Takayasu’s arteritis. Mod. Rheumatol., 2016 Mar 21, 1-4.
8. Mesquida, M.; Victoria, H.M.; Llorenç, V.; Pelegrín, L.; Espinosa, G.; Dick, A.D.; Adán, A. Behçet disease-associated uveitis successfully treated with golimumab. Ocul. Immunol. Inflamm., 2013, 21(2), 160-162.
9. Capuozzo, M.; Ottaiano, A.; Nava, E.; Cascone, S.; Fico, R.; Iaffaioli, R.V.; Cinque, C. Etanercept induces remission of polyarteritis nodosa: A case report. Front Pharmacol., 2014, 3(5), 122.
10. Valor, L.; Monteagudo, I.; de la Torre, I.; Fernández, C.G.; Montoro, M.; Longo, J.L.; Carreño, L. Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanercept. Mod. Rheumatol., 2014, 24(4), 688-689.
11. Melikoglu, M.; Fresko, I.; Mat, C.; Ozyazgan, Y.; Gogus, F.; Yurdakul, S.; Hamuryudan, V.; Yazici, H. Short-term trial of etanercept in Behçet’s disease: A double blind, placebo controlled study. J. Rheumatol., 2005, 32(1), 98-105.
12. Díaz-Llopis, M.; Salom, D.; Garcia-de-Vicuña, C.; Cordero-Coma, M.; Ortega, G.; Ortego, N.; Suarez-de-Figueroa, M.; Rio-Pardo, M.J.; Fernandez-Cid, C.; Fonollosa, A.; Blanco, R.; Garcia-Aparicio, A.M.; Benitez-Del-Castillo, J.M.; Olea, J.L.; Arevalo, J.F. Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients. Ophthalmology, 2012, 119(8), 1575-1581.
13. Perra, D.; Alba, M.A.; Callejas, J.L.; Mesquida, M.; Ríos-Fernández, R.; Adán, A.; Ortego, N.; Cervera, R.; Espinosa, G. Adalimumab for the treatment of Behçet’s disease: Experience in 19 patients. Rheumatology (Oxford)., 2012, 51(10), 1825-1831.
14. Laurino, S.; Chaudhry, A.; Booth, A.; Conte, G.; Jayne, D. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol. Dial Transplant., 2010, 25(10), 3307-3314.
15. Minozzi, S.; Bonovas, S.; Lytras, T.; Pecoraro, V.; González-Lorenzo, M.; Bastiampillai, A.J.; Gabrielli, E.M.; Lonati, A.C.; Moja, L.; Cinquini, M.; Marino, V.; Matucci, A.; Milano, G.M.; Tocci, G.; Scarpa, R.; Goletti, D.; Cantini, F. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis. Expert Opin. Drug Saf., 2016, 15(Supp1), 11-34.
16. Gardam, M.A.; Keystone, E.C.; Menzies, R.; Manners, S.; Skamene, E.; Long, R.; Vinh, D.C. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect. Dis., 2003, 3(3), 148-155.
17. Tubach, F.; Salmon, D.; Ravaud, P.; Allanore, Y.; Goupille, P.; Breban, M.; Pallot-Prades, B.; Pouplin, S.; Sacchi, A.; Chichemanian, R.M.; Bretagne, S.; Emilie, D.; Lemann, M.; Lortholary, O.; Mariette, X. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum., 2009, 60(7), 1884-1894.
18. Vallabhaneni, S.; Chiller, T.M. Fungal infections and new biologic therapies. Curr. Rheumatol. Rep., 2016, 18(5), 29.
19. Cheifetz, A.; Smedley, M.; Martin, S.; Reiter, M.; Leone, G.; Mayer, L.; Plevy, S. The incidence and management of infusion reactions to infliximab: A large center experience. Am. J. Gastroenterol., 2003, 98(6), 1315-1324.
20. Cheifetz, A.; Mayer, L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt. Sinai J. Med., 2005, 72, 250.
21. Maneiro, J.R.; Salgado, E.; Gomez-Reino, J.J. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: Systematic review and meta-analysis. JAMA Intern. Med., 2013, 173(15), 1416-1428.
22. Jani, M.; Barton, A.; Warren, R.B.; Griffiths, C.E.; Chinoy, H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014, 53(2), 213-222.
23. Raaschou, P.; Simard, J.F.; Holmqvist, M.; Askling, J. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: Nationwide population based prospective cohort study from Sweden. BMJ, 2013, 346, f1939.
24. Raaschou, P.; Simard, J.; Asker Hagelberg, C.; Askling, J. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: Cohort study based on nationwide prospectively recorded data from Sweden. BMJ, 2016, i262.
25. Wadström, H.; Frisell, T.; Sparén, P.; Askling, J. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Ann. Rheum. Dis., 2016, 75, 1272-1278.
26. Bonovas, S.; Minozzi, S.; Lytras, T.; Gonzalez-Lorenzo, M.; Pecoraro, V.; Colombo, S.; Polloni, I.; Moja, L.; Cinquini, M.; Marino, V.; Goletti, D.; Matucci, A.; Tocci, G.; Milano, G.M.; Scarpa, R.; Cantini, F. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis. Expert Opin. Drug Saf., 2016, 15(sup1), 35-54.
27. Boross, P.; Leusen, J. Mechanisms of action of CD20 antibodies. Am. J. Cancer Res., 2012, 2(6), 676-690.
28. Stone, J.H.; Merkel, P.A.; Spiera, R.; Seo, P.; Langford, C.A.; Hoffman, G.S.; Kallenberg, C.G.; St Clair, E.W.; Turkiewicz, A.; Tchao, N.K.; Webber, L.; Ding, L.; Sejismundo, L.P.; Mieras, K.; Weitzenkamp, D.; Ikle, D.; Seyfert-Margolis, V.; Mueller, M.; Brunetta, P.; Allen, N.B.; Fervenza, F.C.; Geetha, D.; Keogh, K.A.; Kissin, E.Y.; Monach, P.A.; Peikert, T.; Stegeman, C.; Ytterberg, S.R.; Specks, U. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med., 2010, 363(3), 221-232.
29. Jones, R.B.; Furuta, S.; Tervaert, J.W.; Hauser, T.; Luqmani, R.; Morgan, M.D.; Peh, C.A.; Savage, C.O.; Segelmark, M.; Tesar, V.; van Paassen, P.; Walsh, M.; Westman, K.; Jayne, D.R. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann. Rheum. Dis., 2015, 74(6), 1178-1182.
30. Guillevin, L.; Pagnoux, C.; Karras, A.; Khouatra, C.; Aumaitre, O.; Cohen, P.; Maurier, F.; Decaux, O.; Ninet, J.; Gobert, P.; Quemeneur, T.; Blanchard-Delaunay, C.; Godmer, P.; Puechal, X.; Carron, P.L.; Hatron, P.Y.; Limal, N.; Hamidou, M.; Ducret, M.; Daugas, E.; Papo, T.; Bonnotte, B.; Mahr, A.; Ravaud, P.; Mouthon, L. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med., 2014, 371(19), 1771-1780.
31. Davatchi, F.; Shams, H.; Rezaipoor, M.; Sadeghi-Abdollahi, B.; Shahram, F.; Nadji, A.; Chams-Davatchi, C.; Akhlaghi, M.; Faezi, T.; Naderi, N. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int. J. Rheum. Dis., 2010, 13(3), 246-252.
32. Ferri, C.; Cacoub, P.; Mazzaro, C.; Roccatello, D.; Scaini, P.; Sebastiani, M.; Tavoni, A.; Zignego, A.L.; De Vita, S. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun. Rev., 2011, 11(1), 48-55.
33. Visentini, M.; Ludovisi, S.; Petrarca, A.; Pulvirenti, F.; Zaramella, M.; Monti, M.; Conti, V.; Ranieri, J.; Colantuono, S.; Fognani, E.; Piluso, A.; Tinelli, C.; Zignego, A.L.; Mondelli, M.U.; Fiorilli, M.; Casato, M. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun. Rev., 2011, 10(11), 714-719.
34. De Vita, S.; Quartuccio, L.; Isola, M.; Mazzaro, C.; Scaini, P.; Lenzi, M.; Campanini, M.; Naclerio, C.; Tavoni, A.; Pietrogrande, M.; Ferri, C.; Mascia, M.T.; Masolini, P.; Zabotti, A.; Maset, M.; Roccatello, D.; Zignego, A.L.; Pioltelli, P.; Gabrielli, A.; Filippini, D.; Perrella, O.; Migliaresi, S.; Galli, M.; Bombardieri, S.; Monti, G. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum., 2012, 64(3), 843-853.
35. Sneller, M.C.; Hu, Z.; Langford, C.A. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum., 2012, 64(3), 835-842
36. Visentini, M.; Tinelli, C.; Colantuono, S.; Monti, M.; Ludovisi, S.; Gragnani, L.; Mitrevski, M.; Ranieri, J.; Fognani, E.; Piluso, A.; Granata, M.; De Silvestri, A.; Scotti, V.; Mondelli, M.U.; Zignego, A.L.; Fiorilli, M.; Casato, M. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmun Rev., 2015, 14(10), 889-896.
37. Terrier, B.; Krastinova, E.; Marie, I.; Launay, D.; Lacraz, A.; Belenotti, P.; de Saint-Martin, L.; Quemeneur, T.; Huart, A.; Bonnet, F.; Le Guenno, G.; Kahn, J.E.; Hinschberger, O.; Rullier, P.; Diot, E.; Lazaro, E.; Bridoux, F.; Zenone, T.; Carrat, F.; Hermine, O.; Leger, J.M.; Mariette, X.; Senet, P.; Plaisier, E.; Cacoub, P. Management of noninfectious mixed cryoglobulinemia vasculitis: Data from 242 cases included in the CryoVas survey. Blood, 2012, 119(25), 5996-6004.
38. Terrier, B.; Amoura, Z.; Ravaud, P.; Hachulla, E.; Jouenne, R.; Combe, B.; Bonnet, C.; Cacoub, P.; Cantagrel, A.; de Bandt, M.; Fain, O.; Fautrel, B.; Gaudin, P.; Godeau, B.; Harle, J.R.; Hot, A.; Kahn, J.E.; Lambotte, O.; Larroche, C.; Leone, J.; Meyer, O.; Pallot-Prades, B.; Pertuiset, E.; Quartier, P.; Schaerverbeke, T.; Sibilia, J.; Somogyi, A.; Soubrier, M.; Vignon, E.; Bader-Meunier, B.; Mariette, X.; Gottenberg, J.E. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the french autoimmunity and rituximab registry. Arthritis Rheum., 2010, 62(8), 2458-2466.
39. Leandro, M.J.; Edwards, J.C.; Cambridge, G.; Ehrenstein, M.R.; Isenberg, D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum., 2002, 46(10), 2673-2677.
40. Ramos-Casals, M.; Soto, M.J.; Cuadrado, M.J.; Khamashta, M.A. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus, 2009, 18(9), 767-776.
41. Merrill, J.T.; Neuwelt, C.M.; Wallace, D.J.; Shanahan, J.C.; Latinis, K.M.; Oates, J.C.; Utset, T.O.; Gordon, C.; Isenberg, D.A.; Hsieh, H.J.; Zhang, D.; Brunetta, P.G. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum., 2010, 62(1), 222-233.
42. Rovin, B.H.; Furie, R.; Latinis, K.; Looney, R.J.; Fervenza, F.C.; Sanchez-Guerrero, J.; Maciuca, R.; Zhang, D.; Garg, J.P.; Brunetta, P.; Appel, G. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum., 2002, 64(4), 1215-1226.
43. Fraticelli, P.; De Vita, S.; Franzolini, N.; Svegliati, S.; Scott, C.A.; Tonnini, C.; Spadoni, T.; Gabrielli, B.; Pomponio, G.; Moroncini, G.; Gabrielli, A. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Clin. Exp. Rheumatol., 2015, 33(4 Suppl 91), S160-167.
44. Daoussis, D.; Melissaropoulos, K.; Sakellaropoulos, G.; Antonopoulos, I.; Markatseli, T.E.; Simopoulou, T.; Georgiou, P.; Andonopoulos, A.P.; Drosos, A.A.; Sakkas, L.; Liossis, S.N. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin. Arthritis Rheum., 2016, 46(5), 625-631.
45. Jordan, S.; Distler, J.H.; Maurer, B.; Huscher, D.; van Laar, J.M.; Allanore, Y.; Distler, O. Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Arthritis Rheum. Dis., 2015, 74(6), 1188-1194.
46. Kowal-Bielecka, O.; Fransen, J.; Avouac, J.; Becker, M.; Kulak, A.; Allanore, Y.; Distler, O.; Clements, P.; Cutolo, M.; Czirjak, L.; Damjanov, N.; Del Galdo, F.; Denton, C.P.; Distler, J.H.W.; Foeldvari, I.; Figelstone, K.; Frerix, M.; Furst, D.E.; Guiducci, S.; Hunzelmann, N.; Khanna, D.; Matucci-Cerinic, M.; Herrick, A.L.; van den Hoogen, F.; van Laar, J.M.; Riemekasten, G.; Silver, R.; Smith, V.; Sulli, A.; Tarner, I.; Tyndall, A.; Welling, J.; Wigley, F.; Valentini, G.; Walker, U.A.; Zulian, F.; Muller-Ladner, U. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis., 2017, 76(8), 1327-1339.
47. Gottenberg, J.E.; Cinquetti, G.; Larroche, C.; Combe, B.; Hachulla, E.; Meyer, O.; Pertuiset, E.; Kaplanski, G.; Chiche, L.; Berthelot, J.M.; Gombert, B.; Goupille, P.; Marcelli, C.; Feuillet, S.; Leone, J.; Sibilia, J.; Zarnitsky, C.; Carli, P.; Rist, S.; Gaudin, P.; Salliot, C.; Piperno, M.; Deplas, A.; Breban, M.; Lequerre, T.; Richette, P.; Ghiringhelli, C.; Hamidou, M.; Ravaud, P.; Mariette, X. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann. Rheum. Dis., 2013, 72(6), 1026-1031.
48. Kasi, P.M.; Tawbi, H.A.; Oddis, C.V.; Kulkarni, H.S. Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit. Care, 2012, 16(4), 231.
49. Kelesidis, T.; Daikos, G.; Boumpas, D.; Tsiodras, S. Does rituximab increase the incidence of infectious complications? A narrative review. Int. J. Infect. Dis., 2011, 15(1), e2-16.
50. Tsutsumi, Y.; Yamamoto, Y.; Ito, S.; Ohigashi, H.; Shiratori, S.; Naruse, H.; Teshima, T. Hepatitis B virus reactivation with a rituximab-containing regimen. World J. Hepatol., 2015, 7(21), 2344-2351.
51. Mysler, E.F.; Spindler, A.J.; Guzman, R.; Bijl, M.; Jayne, D.; Furie, R.A.; Houssiau, F.A.; Drappa, J.; Close, D.; Maciuca, R.; Rao, K.; Shahdad, S.; Brunetta, P. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum., 2013, 65(9), 2368-2379.
52. Navarra, S.V.; Guzman, R.M.; Gallacher, A.E.; Hall, S.; Levy, R.A.; Jimenez, R.E.; Li, E.K.; Thomas, M.; Kim, H.Y.; Leon, M.G.; Tanasescu, C.; Nasonov, E.; Lan, J.L.; Pineda, L.; Zhong, Z.J.; Freimuth, W.; Petri, M.A. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet, 2011, 377(9767), 721-731.
53. Furie, R.; Petri, M.; Zamani, O.; Cervera, R.; Wallace, D.J.; Tegzova, D.; Sanchez-Guerrero, J.; Schwarting, A.; Merrill, J.T.; Chatham, W.W.; Stohl, W.; Ginzler, E.M.; Hough, D.R.; Zhong, Z.J.; Freimuth, W.; van Vollenhoven, R.F. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum., 2011, 63(12), 3918-3930.
54. Stohl, W.; Schwarting, A.; Okada, M.; Scheinberg, M.; Doria, A.; Hammer, A.E.; Kleoudis, C.; Groark, J.; Bass, D.; Fox, N.L.; Roth, D.; Gordon, D. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol., 2017, 69(5), 1016-1027.
55. Ginzler, E.M.; Wax, S.; Rajeswaran, A.; Copt, S.; Hillson, J.; Ramos, E.; Singer, N.G. Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res. Ther., 2012, 14(1), R33.
56. Mertens, M.; Singh, J.A. Anakinra for rheumatoid arthritis: a systematic review. J. Rheumatol., 2009, 36(6), 1118-1125.
57. Fitzgerald, A.A.; Leclercq, S.A.; Yan, A.; Homik, J.E.; Dinarello, C.A. Rapid responses to anakinra in patients with refractory adultonset Still’s disease. Arthritis Rheum., 2005, 52(6), 1794-1803.
58. Kalliolias, G.D.; Georgiou, P.E.; Antonopoulos, I.A.; Andonopoulos, A.P.; Liossis, S.N. Anakinra treatment in patients with adultonset Still’s disease is fast, effective, safe and steroid sparing: Experience from an uncontrolled trial. Ann. Rheum. Dis., 2007, 66(6), 842-843.
59. Giampietro, C.; Ridene, M.; Lequerre, T.; Costedoat Chalumeau, N.; Amoura, Z.; Sellam, J.; Sibilia, J.; Bourgeois, P.; Fautrel, B., Anakinra in adult-onset Still’s disease: Long-term treatment in patients resistant to conventional therapy. Arthritis Care Res., (Hoboken), 2013, 65(5), 822-826.
60. Ortiz-Sanjuan, F.; Blanco, R.; Riancho-Zarrabeitia, L.; Castaneda, S.; Olive, A.; Riveros, A.; Velloso-Feijoo, M.L.; Narvaez, J.; Jimenez-Moleon, I.; Maiz-Alonso, O.; Ordonez, C.; Bernal, J.A.; Hernandez, M.V.; Sifuentes-Giraldo, W.A.; Gomez-Arango, C.; Galindez-Agirregoikoa, E.; Blanco-Madrigal, J.; Ortiz-Santamaria, V.; del Blanco-Barnusell, J.; De Dios, J.R.; Moreno, M.; Fiter, J.; de los Riscos, M.; Carreira, P.; Rodriguez-Valls, M.J.; Gonzalez-Vela, M.C.; Calvo-Rio, V.; Loricera, J.; Palmou-Fontana, N.; Pina, T.; Llorca, J.; Gonzalez-Gay, M.A. efficacy of anakinra in refractory adult-onset Still’s disease: Multicenter study of 41 patients and literature review. Medicine (Baltimore), 2015, 94(39), e1554.
61. Kuemmerle-Deschner, J.B.; Haug, I. Canakinumab in patients with cryopyrin-associated periodic syndrome: An update for clinicians. Ther. Adv. Musculoskelet. Dis., 2013, 5(6), 315-329.
62. Ortiz-Sanjuan, F.; Blanco, R.; Calvo-Rio, V.; Narvaez, J.; Rubio Romero, E.; Olive, A.; Castaneda, S.; Gallego Flores, A.; Hernandez, M.V.; Mata, C.; Ros Vilamajo, I.; Sifuentes Giraldo, W.A.; Caracuel, M.A.; Freire, M.; Gomez Arango, C.; Llobet, J.; Manrique Arija, S.; Marras, C.; Moll-Tuduri, C.; Plasencia-Rodriguez, C.; Rosello, R.; Urruticoechea, A.; Velloso-Feijoo, M.L.; Del Blanco, J.; Gonzalez-Vela, M.C.; Rueda-Gotor, J.; Pina, T.; Loricera, J.; Gonzalez-Gay, M.A. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: Multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol., 2014, 66(6), 1659-1665.
63. Villiger, P.M.; Adler, S.; Kuchen, S.; Wermelinger, F.; Dan, D.; Fiege, V.; Butikofer, L.; Seitz, M.; Reichenbach, S. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet, 2016, 387(10031), 1921-1927.
64. Stone, J.H.; Tuckwell, K.; Dimonaco, S.; Klearman, M.; Aringer, M.; Blockmans, D.; Brouwer, E.; Cid, M.C.; Dasgupta, B.; Rech, J.; Salvarani, C.; Spiera, R.F.; Unizony, S.H.; Collinson, N. Efficacy and safety of tocilizumab in patients with giant cell arteritis: primary and secondary outcomes from a phase 3, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol., 2016, 68(suppl 10).
65. Salvarani, C.; Magnani, L.; Catanoso, M.; Pipitone, N.; Versari, A.; Dardani, L.; Pulsatelli, L.; Meliconi, R.; Boiardi, L. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford), 2012, 51(1), 151-156.
66. Unizony, S.; Arias-Urdaneta, L.; Miloslavsky, E.; Arvikar, S.; Khosroshahi, A.; Keroack, B.; Stone, J.R.; Stone, J.H. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res., (Hoboken), 2012, 64(11), 1720-1729.
67. Seitz, M.; Reichenbach, S.; Bonel, H.M.; Adler, S.; Wermelinger, F.; Villiger, P.M. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med. Wkly., 2011, 141, w13156.
68. Salvarani, C.; Magnani, L.; Catanoso, M.G.; Pipitone, N.; Versari, A.; Dardani, L.; Pulsatelli, L.; Meliconi, R.; Boiardi, L. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin. Exp. Rheumatol., 2012, 30(1 Suppl 70), S90-93.
69. Bredemeier, M.; Rocha, C.M.; Barbosa, M.V.; Pitrez, E.H. Oneyear clinical and radiological evolution of a patient with refractory Takayasu’s arteritis under treatment with tocilizumab. Clin. Exp. Rheumatol., 2012, 30(1 Suppl 70), S98-100.
70. Sakai, R.; Cho, S.K.; Nanki, T.; Watanabe, K.; Yamazaki, H.; Tanaka, M.; Koike, R.; Tanaka, Y.; Saito, K.; Hirata, S.; Amano, K.; Nagasawa, H.; Sumida, T.; Hayashi, T.; Sugihara, T.; Dobashi, H.; Yasuda, S.; Sawada, T.; Ezawa, K.; Ueda, A.; Fujii, T.; Migita, K.; Miyasaka, N.; Harigai, M. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: Results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res. Ther., 2015, 17, 74.
71. Van Vollenhoven, R.; Rovin, B.; Wagner, C.; Zhou, B.; Gordon, R.; Hsu, B. A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the Biologics and small molecules in LN 519 efficacy and safety of sirukumab in patients with active lupus nephritis. Ann. Rheum. Dis., 2014, 73(Suppl 2), 78.
72. Furie, R.; Khamashta, M.; Merrill, J.T.; Werth, V.P.; Kalunian, K.; Brohawn, P.; Illei, G.G.; Drappa, J.; Wang, L.; Yoo, S. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol., 2017, 69(2), 376-386.
73. Khamashta, M.; Merrill, J.T.; Werth, V.P.; Furie, R.; Kalunian, K.; Illei, G.G.; Drappa, J.; Wang, L.; Greth, W. Sifalimumab, an antiinterferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: A randomised, double-blind, placebocontrolled study. Ann. Rheum. Dis., 2016, 75(11), 1909-1916.
74. Clowse, M.E.; Wallace, D.J.; Furie, R.A.; Petri, M.A.; Pike, M.C.; Leszczynski, P.; Neuwelt, C.M.; Hobbs, K.; Keiserman, M.; Duca, L.; Kalunian, K.C.; Galateanu, C.; Bongardt, S.; Stach, C.; Beaudot, C.; Kilgallen, B.; Gordon, C. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind, placebocontrolled trials. Arthritis Rheumatol., 2017, 69(2), 362-375.